Campbell Rogers, Chief Medical Officer of Heartflow, Inc. (NASDAQ:HTFL), filed a Form 4 on November 19, 2026, disclosing a series of sales and option exercises in Heartflow common stock across multiple trusts and directly held accounts, with the earliest transaction dated November 17, 2026.

Key Highlights

  • Option exercises on Nov 17, 2026: Rogers exercised stock options covering 12,328 shares at $8.33 and 5,101 shares at $2.22, both held directly.
  • Direct share sale on Nov 17, 2026: Rogers sold 24,188 shares of common stock at $46.39 per share, reducing directly held shares to 64,424.
  • Indirect trust sales on Nov 17, 2026: 5,654 shares were sold from the Campbell Rogers 2019 Irrevocable Trust and 6,503 shares from the Spouse's Trust, both at $46.39.
  • Earlier sales under a separate 10b5-1 plan: Three sales totaling 50,754 shares were made between February 20 and April 1, 2026, from the Campbell Rogers Revocable Trust at prices of $24.40 (weighted average), $25.00, and $24.67.
  • Remaining beneficial ownership: Following all reported transactions, Rogers directly held 64,424 shares, with additional indirect holdings including 46,159 shares in the CR Asset Protection Trust of 2023.
  • 10b5-1 plans cited: The November 17, 2026 transactions were effected under a Rule 10b5-1 trading plan adopted June 16, 2026; the earlier 2026 sales were under a plan adopted September 12, 2025.

Campbell Rogers' November 2026 Transactions at Heartflow

According to the filing, Campbell Rogers, serving as Chief Medical Officer of Heartflow, Inc., reported multiple transactions in Heartflow common stock across both directly held and indirectly held accounts. On November 17, 2026, Rogers exercised two sets of stock options: 12,328 shares at an exercise price of $8.33 per share, and 5,101 shares at $2.22 per share. The filing notes that the 12,328-share options are fully exercisable, while the 5,101-share options vest in monthly installments until July 1, 2027, subject to continued service. Both exercises carried a derivative security price of $0.

Also on November 17, 2026, Rogers sold 24,188 shares directly at $46.39 per share. The filing states this sale includes 6,759 shares of common stock held outright and 17,429 shares acquired through the option exercise. Additionally, 5,654 shares held indirectly through the Campbell Rogers 2019 Irrevocable Trust and 6,503 shares held through the Spouse's Trust were each sold at $46.39 per share on the same date. After these transactions, Rogers held 64,424 shares directly. Indirect holdings reported include shares in the Campbell Rogers 2019 Irrevocable Trust, the Spouse's Trust, and 46,159 shares in the CR Asset Protection Trust of 2023.

The filing also covers earlier 2026 sales from the Campbell Rogers Revocable Trust: 16,918 shares on February 20, 2026 at a weighted average price of $24.40 (ranging from $22.46 to $26.55); 16,918 shares on March 19, 2026 at $25.00; and 16,918 shares on April 1, 2026 at $24.67. Those transactions were made under a Rule 10b5-1 plan adopted September 12, 2025. The November transactions were executed under a separate plan adopted June 16, 2026. The form was signed by Mhairi Jones under power of attorney on November 19, 2026.

What Was Disclosed

Heartflow, Inc.'s Chief Medical Officer, Campbell Rogers, disclosed sales of common stock and exercises of stock options across directly and indirectly held accounts between February and November 2026, all attributed to Rule 10b5-1 trading plans, via a Form 4 filed November 19, 2026.